Supplemental Brazil info in Fall 99:"Biobras, Biotech's licensee in Brazil,.."
biotechltd.com
Friday, September 17, 1999
--------------------------------------------------------------------------------
Results from Brazil Clinical Trial of Biotech Holdings'
BIOTECH HOLDINGS LTD ("BIO-Y;BIOHF-L") - Results from Brazil Clinical Trial of Biotech Holdings'
Robert B. Rieveley, President of Biotech Holdings Ltd. ("Biotech") announced a summary of results of Biotech's recently completed clinical trial in Brazil.
"The purpose of the clinical trial," Mr. Rieveley said, "was to provide supplementary information for a regulatory application for approval of our diabetes drug, DIAB II, in Brazil as a prescription treatment for Type II or Adult-Onset Diabetes."
Mr. Rieveley noted that the trial was carried out by one of the largest independent contract research laboratories in Brazil, working with Brazilian doctors specializing in diabetes. Trial design was reviewed by Biotech and by Biobras S.A ("Biobras"). Biobras, Biotech's licensee in Brazil, is the fourth largest insulin manufacturer in the world and formerly a subsidiary of Eli Lilly.
The study evaluated the effect on diagnosed Type II diabetics of replacing their usual diabetes medication with DIAB II. On enrolling in the study, patients continued their normal activity and eating patterns while patients' drug regimens were switched to DIAB II twice daily.
Parameters measured included plasma insulin, HDL and LDL cholesterol, triglycerides and glycosylated hemoglobin (Hb A1c), a key indicator of diabetes control. Toxicity monitoring and monitoring of weight, blood pressure, heart rate and temperature was carried out during multiple laboratory visits during a period of eight weeks.
During DIAB II treatment, no hepatic or other organ toxicity was detected in laboratory tests and no adverse clinical events were reported. Plasma insulin, HDL/LDL ratio and triglycerides were controlled equally well with DIAB II treatment as on the patients' accustomed medication. The critical Hb A1c measurement showed reduced levels during the course of the study, to an average of 5.85%, indicating excellent diabetic control. It was noted that patients on average also experienced weight loss during the course of the trial.
"Results of the Brazil trial," Mr. Rieveley pointed out, "are in line with earlier results from China, where DIAB II is sold as a prescription drug. With a demonstrated lack of the toxicity that characterizes some insulin-sensitizing drugs and with demonstrated efficacy, we believe that DIAB II should become the market leader for insulin-sensitizing drugs wherever introduced."
DIAB II, an oral diabetes drug, is an insulin-receptor sensitizer, a new class of drugs for controlling the chronically high blood sugar level that typifies diabetes. DIAB II works by improving the patient's ability to utilize both endogenous and injected insulin, the hormone that regulates blood sugar levels. Type II Diabetes affects more than 15 million people in the United States, over 20 million in Latin America and over 150 million people worldwide.
Biotech Holdings is located in Vancouver, British Columbia, Canada with its plant in Richmond, B.C. Biotech Holdings' shares trade on the Over the Counter Bulletin Board and on the Alberta Stock Exchange. For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free) 8 a.m. to 5 p.m. Pacific time, or by e-mail at For further information, please visit Biotech's website at
This release contains forward-looking statements within the meaning of Section 21 E of the Securities and Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ for reasons that include but are not limited to political and economic conditions in the countries in which the Company does or intends to do business, regulatory action, product pricing and competitive market conditions. These forward-looking statements represent the Company's judgement at the date of this release and any changes in assumptions or external factors could produce significantly different results. TEL: (604) 736-3351
Biotech Holdings Ltd FAX: (604) 736-3806
biz.yahoo.com
ImmuNis Announces that DIAB II Manufacturing Facility Nears Certification
FAIRFIELD, N.J., Nov. 22 /PRNewswire/ -- ImmuNis Corp.'s (OTC Bulletin Board: IMMC - news) President, Colin Leech-Porter, announced today that the specialized controlled-environmental area for the production of DIAB II at Biotech Holdings Ltd.'s Richmond, British Columbia facility is nearly complete and is expected to receive government certification in the near future.
Colin Leech-Porter stated that, ''The completion of this facility and the work being done by Biotech to be in a position to manufacture and deliver DIAB II this coming year is an important milestone in bring this revolutionary new drug to the market. We believe that the progress made by Biotech this past year in forming partnerships with pharmaceutical companies in Latin America, and now in North America, indicate the acceptance of DIAB II by the experts in the industry.
DIAB II is a revolutionary oral drug for treatment of Adult-Onset Diabetes -- an illness affecting more than 15 million Americans and more than 150 million people around the world. The drug -- DIAB II -- provides excellent control of diabetes symptoms without the side-effects of many competing drugs. DIAB II works by improving the patient's ability to utilize both endogenous and injected insulin, the hormone that controls blood sugar levels.
DIAB II was developed by Biotech Holdings Ltd., a Canadian-based pharmaceutical company, which controls the worldwide manufacturing and marketing rights to the drug. ImmuNis purchased a 25% interest in the commercial rights to DIAB II in 1998 for territories outside of Oriental Asia. Biotech Holding is positioning DIAB II to become a leader in the $10-Billion annual market for oral Type II Diabetes medications.
Colin Leech-Porter further stated, ''As part of a June 9, 1999 announcement Biotech Holdings Ltd. pointed out that there is a sizable and very lucrative market potential for DIAB II in Latin America -- that for each one percent of the diabetic population in Brazil, Argentina and Venezuela using DIAB II (a total of 100,000 one-year prescriptions) -- DIAB II gross sales revenues generated would be over $20,000,000 annually. Based on this ImmuNis could have the potential to bring net revenues to ImmuNis in excess of $30 million per year. Other estimates indicate that DIAB II sales have the potential to reach $200 million a year in the United States.''
ImmuNis Corp. owns interests and invests in innovative health care modalities that address health problems afflicting populations in both developing countries and Western nations. The Company's interests may be in the form of strategic partnerships, direct ownership interest in patents, or participation in or control of commercial or marketing rights.
For more information, contact Rich Kaiser at YES International Investor Relations Services, (800) 631-8127 or visit the company' information site at www.yesinternational.com/immc.
This release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ for reasons that include but are not limited to political and economic conditions in the countries in which the Company does or intends to do business, regulatory action, product pricing and competitive market conditions. These forward-looking statements represent the Company's judgment at the date of this release and any changes in assumptions or external factors could produce significantly different results.
SOURCE: ImmuNis Corp.
--------------------------------------------------------------------------------
More Quotes and News: ImmuNis Corp (OTC BB:IMMC.OB - news)
Related News Categories: biotech, health care, medical/pharmaceutical
Chucka - PR disclosure info at refering post ( this is from a RB discussion this week), IMPACT of the future we all hope.
P.S.- Back to the $2 level on low volume while activity and interest may rise, have a nice weekend all longs!RE:(( This is a PINK SHEET and one must tell ones broker in the instruction with a full service broker I do believe after he says to you, I need a quote ...))Here is now:
IMMC - IMMUNIS CORP - Company Website yesinternational.com
Trade times are local to the exchange. News times are Pacific. Bid/ask/vol sizes in thousands. Sym-X Bid - Ask Last Chg % Vol $Vol #tr Open-Hi-Lo Year Hi-Lo last trade News delay
IMMC - Q no orders 2 0.7 1 2 2 2 2 2-1/4 3/8 Feb 4 09:38 15 min
Last 2 trades today Time X Price Vol
09:38:00 Q 2.0 200
09:32:50 Q 2.0 500
canada-stockwatch.com
ChuckaPR Guy |
